Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Rhea-AI Summary

Nektar (Nasdaq: NKTR) will host an investor call and live webcast on February 10, 2026 at 8:00 am ET to review topline results from the 36‑week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis.

According to the company, a morning press release will publish the results, slides will be posted on the Nektar investor events page, and a replay will be available for at least 30 days.

News Market Reaction – NKTR

+51.07% 12.2x vol

96 alerts

+51.07% Session close to close

+52.3% Peak Tracked

-24.0% Trough Tracked

$1.15B Market Cap

12.2x Rel. Volume

In the Feb 10 session, NKTR gained 51.07%, reflecting a significant positive market reaction. Argus tracked a peak move of +52.3% during that session. Argus tracked a trough of -24.0% from its starting point during tracking. Our momentum scanner triggered 96 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 12.2x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +51.1% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +51.1% in the session following this news. A strong positive reaction aligns with the market’s focus on upcoming clinical catalysts. This announcement set expectations for topline 36-week REZOLVE-AD maintenance data, following earlier positive REZOLVE-AD signals and mixed but advancing REZOLVE-AA results. Historically, conference-call notices under this tag saw an average move of -2.56%, so a large upside move would have represented a notable departure and could have been vulnerable to reversal once detailed data were released.

Key Figures

Maintenance period length: 36-week Trial phase: Phase 2b Conference call date: February 10, 2026 +2 more

5 metrics

Maintenance period length 36-week REZOLVE-AD Phase 2b maintenance period topline results

Trial phase Phase 2b REZOLVE-AD study of rezpegaldesleukin

Conference call date February 10, 2026 Investor call to discuss 36-week REZOLVE-AD maintenance results

Start time ET 8:00 am ET Scheduled time for investor webcast

Start time PT 5:00 am PT Scheduled time for investor webcast

Previous Conferences,clinical trial Reports

1 past event · Latest: Dec 15 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 15	Data call announcement	Neutral	-2.6%	Scheduled webcast to review topline 36-week REZOLVE-AA induction results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior similar conference/clinical webcast news for rezpegaldesleukin saw a modest negative move, indicating that scheduling calls alone has not historically driven sustained upside.

Recent Company History

Over the last several months, Nektar has steadily advanced rezpegaldesleukin across indications. On Nov 8, 2025, REZOLVE-AD Phase 2b data showed statistically significant improvements in asthma control and atopic dermatitis endpoints. In December 2025, the company scheduled and then reported 36-week REZOLVE-AA Phase 2b results, which narrowly missed the primary endpoint in the main analysis but achieved significance in a sensitivity analysis. The current announcement fits this pattern of structured data rollouts via scheduled investor webcasts.

Key Terms

phase 2b, regulatory t-cell, treg, atopic dermatitis, +1 more

5 terms

phase 2b medical

"Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

regulatory t-cell medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator"

Regulatory T cell (often called a Treg) is a type of white blood cell that acts like a brake or thermostat for the immune system, calming or shutting down immune reactions to prevent damage to healthy tissue. For investors, Tregs matter because drugs or therapies that boost, block, or reprogram these cells can treat a range of conditions—autoimmune disease, transplant rejection, and cancer—so changes in Treg science can drive new drug pipelines and market opportunities.

treg medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator"

Treg, short for regulatory T cell, is a type of immune cell that acts like a brake on the immune system, calming or suppressing immune responses to prevent excessive inflammation or attack on the body's own tissues. For investors, therapies that boost or block Tregs can change the commercial outlook for drugs treating autoimmune diseases, organ transplant rejection or cancer, because shifting this balance can determine a treatment’s effectiveness and safety.

atopic dermatitis medical

"for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

webcast technical

"will host an investor call and live webcast to review topline results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT. 

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com 

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-maintenance-period-for-its-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-in-atopic-dermatitis-on-february-10-2026-302682916.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) present topline results from the REZOLVE-AD 36-week maintenance period?

Nektar will present results on February 10, 2026 at 8:00 am ET via an investor call and live webcast. According to the company, a morning press release will publish topline data and accompanying slides will be posted on the investor events page.

How can investors access the NKTR webcast for the REZOLVE-AD Phase 2b results on February 10, 2026?

Investors can access the live webcast via the link on Nektar's investor events page. According to the company, the press release, slides, and a replay will be posted on the events section and replayed for at least 30 days.

What results will Nektar (NKTR) discuss during the February 10, 2026 presentation?

Nektar will discuss topline results from the 36-week maintenance period of the Phase 2b REZOLVE-AD trial of rezpegaldesleukin. According to the company, the presentation will summarize the maintenance-period efficacy and safety topline findings for moderate-to-severe atopic dermatitis.

Will the NKTR presentation on February 10 include slides and a replay for REZOLVE-AD topline results?

Yes. According to the company, slides and the press release will be posted on the Nektar events page, and a replay of the webcast will be available for at least 30 days after the February 10, 2026 event.

What is rezpegaldesleukin and why is Nektar (NKTR) reporting REZOLVE-AD maintenance results?

Rezpegaldesleukin is an investigational regulatory T-cell proliferator being studied for atopic dermatitis. According to the company, the February 10 presentation will report topline 36-week maintenance data from the Phase 2b REZOLVE-AD trial to inform investors on efficacy and safety.

Will the February 10, 2026 NKTR webcast include full data or just topline REZOLVE-AD results?

The company will provide topline results during the call and morning press release; full datasets are not guaranteed at the event. According to the company, slides will summarize topline findings and further details may follow in subsequent filings or presentations.